© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Melanoma | Clinical
Phase 3 Study Shows Statistically Significant Survival With Tebentafusp in Metastatic Uveal Melanoma
November 24, 2020
Overall survival was statistically significantly improved with tebentafusp compared with investigator’s choice of therapy as treatment of patients with metastatic uveal melanoma in the phase 3 IMCgp100-202 study.
Plasmid IL-12 Added to Pembrolizumab Elicits Deep and Durable Responses in Advanced Melanoma
November 11, 2020
The strategy of adding the plasmid IL-12 agent tavokinogene telseplasmid to pembrolizumab led to deep systemic responses in patients with actively progressing anti–PD-1–refractory advanced melanoma, according to interim results from the KEYNOTE-695 clinical trial.
Selecting I/O or Targeted Therapy as Adjuvant Treatment of BRAF-Mutant Melanoma
November 05, 2020
During a virtual presentation for the 38th Annual Chemotherapy Foundation Symposium, Janice M. Mehnert, MD explained the science behind selecting the optimal adjuvant therapy for patients with BRAF-mutant melanoma. The options Mehnert weighed were immunotherapy and BRAF-targeted therapy.
Spartalizumab Triplet Does Not Improve PFS in Metastatic Melanoma
September 20, 2020
The phase 3 COMBI-I clinical trial of spartalizumab plus dabrafenib and trametinib showed no improvement in investigator-assessed progression-free survival in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, missing the primary end point in part 3 of the study.
PFS End Point Missed With Spartalizuamb, Dabrafenib, and Trametinib in Melanoma
September 19, 2020
The primary end point of investigator-assessed progression-free survival was missed in part 3 of the randomized, Phase 3 COMBI-i study of spartalizumab in combination with dabrafenib and trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, according to results presented at the 2020 ESMO Virtual Congress.
Sequencing Immunotherapy After Encorafenib and Binimetinib Showed Higher PFS in Metastatic Melanoma
September 19, 2020
The use of encorafenib and binimetinib followed by immunotherapy demonstrated a higher progression-free survival, as well as an objective response rate and median PFS at 1 and 2 years that were consistent with those reported in pivotal studies, according to a presentation by Paolo Ascierto, MD, at the 2020 ESMO Virtual Congress.
COMBI-i Regimen Does Not Improve PFS in Unresectable or Metastatic BRAF V600E-Mutant Melanoma
August 24, 2020
Progression-free survival was not improved with the combination of spartalizumab, dabrafenib, and trametinib when administered as treatment of untreated patients with unresectable or metastatic BRAF V600E-mutant cutaneous melanoma compared with dabrafenib plus trametinib alone, missing the primary end point of the phase 3 COMBI-I clinical trial.
First-Line Pembrolizumab Demonstrates Promising Activity in Phase 2 of Cutaneous Squamous Cell Carcinoma
August 07, 2020
Frontline treatment with the immune checkpoint inhibitor pembrolizumab as monotherapy generated promising activity against cutaneous squamous cell carcinoma with durable responses and a manageable safety profile.
Dendritic Cell Vaccine Shows Long-Term Survival Benefit in High-Risk Melanoma
August 06, 2020
The final data of a personalized tumor lysate, particle-loaded, dendritic cell vaccine demonstrated that patients with stage III or IV melanoma with high-risk of recurrence after complete surgical resection had better survival benefit and disease-free survival rate with the vaccine over placebo, according to a press release from Elios Therapeutics.
FDA Approves Atezolizumab Triplet Regimen for Treatment of Advanced BRAF-Mutant Melanoma
July 30, 2020
The FDA granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600E-mutated advanced melanoma.